Evaluation of the Safety and Efficacy of Sup19 CAR-T Cells in Patients With Previously Failed CD19-Targeted Therapy or CD19-Weakly Expressed Hematologic Tumors
Clinical trial NCT07539610 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07539610
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2026-04-01
- Primary completion
- 2027-11-01
- Enrollment
- 9
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.